Camoteskimab not checked
Apollo Therapeutics Ltd · AEVI-007 · APL-9109
FollowEvery change as it happens, and a Monday email
Trials
1 active
4 in total · 1 in the EU
What this is
- How it works
- An antibody: a lab-made immune protein built to latch onto one target in the body.-mab: monoclonal antibodies WHO name stem
- Tested for
- Atopic Dermatitis, Atopic, Dermatitis, Dermatitis, Atopic, Dermatologic Disease, Eczema, Eczema Atopic Dermatitis, Eczema, Atopic
- Main trialPhase 2
- “This is a phase 2b, multicenter, randomized, double-blind, placebo-controlled study.”In the company’s words, NCT07599813 on ClinicalTrials.gov
- Other names
- AEVI-007 · APL-9109 · AVTX-007 · CERC-007 · MEDI2338
Other drugs for Atopic Dermatitis
Coming up1
- 31 Oct 2027Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials4
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Recruiting | 31 Oct 2027 | A Phase 2b Study of the Effects of Camoteskimab in Adults With Moderate-to-Severe Atopic Dermatitis | |
| Phase 2Completed | 26 Mar 2025 | A Study of the Effects of Camoteskimab in Adults With Moderate to Severe Atopic Dermatitis | |
| Phase 1Completed | 30 Mar 2022 | Phase 1b Study of AEVI-007 in Subjects With Relapsed or Refractory Multiple Myeloma | |
| Phase 1Terminated | 24 May 2022 | A Study to Evaluate Camoteskimab in Participants With Still's Disease |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026